+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Disulfiram Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Disulfiram Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Disulfiram Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6082578
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Disulfiram Market grew from USD 392.75 million in 2024 to USD 412.73 million in 2025. It is expected to continue growing at a CAGR of 4.85%, reaching USD 521.90 million by 2030.

Disulfiram has held a pivotal role in the management of alcohol dependence for decades, offering a proven mechanism to deter consumption through aldehyde dehydrogenase inhibition. Its therapeutic significance has expanded beyond traditional use to encompass opioid use disorders as both adjunct treatment and maintenance therapy, reflecting a broader clinical footprint. This executive summary delves into the evolving Disulfiram market by examining emerging treatment paradigms, regulatory drivers, and shifts in patient engagement.

By mapping recent developments in formulation innovation, patient-centric segmentation, and distribution channels, stakeholders acquire a 360° perspective on current dynamics without relying on market sizing or forecasting. Instead, this analysis focuses on actionable intelligence, enabling pharmaceutical leaders, generics manufacturers, clinical program directors, and policy influencers to align R&D strategies, optimize supply chains, and anticipate regulatory shifts. With a thorough assessment of 2025 tariff impacts, regional differentiators, competitive initiatives, and targeted recommendations, this introduction sets the stage for informed decision-making and strategic planning in the Disulfiram landscape.

Transformative Shifts Redefining the Disulfiram Landscape

Over the last five years, the Disulfiram landscape has undergone transformative shifts driven by regulatory innovation, evolving patient expectations, and advances in delivery technologies. Increased scrutiny of opioid dependence has elevated Disulfiram’s role as an adjunct therapy, prompting clinical trials that explore its synergistic potential with emerging pharmacotherapies. Simultaneously, policymakers in key markets have introduced streamlined pathways for repurposed drugs, reducing time-to-market and encouraging off-label research

Digital health interventions and telemedicine have redefined patient engagement, enabling virtual monitoring of adherence and adverse events. This shift has fostered partnerships between pharmaceutical firms and telehealth platforms, extending Disulfiram’s reach into under-served communities. On the private sector front, wellness programs are integrating pharmacological support with behavioral therapies, reflecting a holistic approach to addiction management. Concurrently, advances in formulation science-particularly long-acting injectables-promise to mitigate compliance challenges and differentiate Disulfiram in a crowded generics space.

Taken together, these trends signal a paradigm shift from volume-driven supply to value-driven outcomes, setting the stage for an era of targeted interventions, strategic collaborations, and patient-centric service models.

Cumulative Impact of U.S. Tariffs on Disulfiram Market Dynamics in 2025

In 2025, newly imposed U.S. tariffs on active pharmaceutical ingredients and finished formulations have created notable downstream effects across the Disulfiram value chain. Import duties on raw materials sourced from major manufacturing hubs have elevated production costs for generics suppliers, prompting a recalibration of procurement strategies. Some manufacturers have accelerated on-shore API synthesis investments to mitigate volatility, while others have pursued strategic alliances with domestic chemical producers to secure preferential pricing.

These tariffs have also influenced pricing strategies, with wholesalers and distributors under pressure to absorb or pass through incremental costs. In response, a segment of market players is negotiating long-term supply agreements to lock in lower tariff-inclusive rates, while payers are reassessing formularies to favor cost-effective therapies. The tariff environment has further underscored the importance of lean manufacturing and batch optimization to preserve margins.

From a clinical perspective, providers face tighter budget constraints and may prioritize higher-value formulations-such as long-acting injectables with adherence advantages-to offset tariff-driven budgetary pressures. Overall, the 2025 tariff landscape reinforces the critical need for supply chain resilience, dynamic pricing models, and agile operational frameworks.

Key Insights from Multi-Dimensional Market Segmentation

Under therapeutic application, the market is studied across alcohol dependence, antabuse therapy and opioid use disorders. The alcohol dependence segment encompasses long-term rehabilitation, relapse prevention and short-term treatment. Antabuse therapy is further differentiated into combination therapy and monotherapy, while opioid use disorders are addressed through adjunct treatment and maintenance therapy.

Formulation type distinguishes between injectable formulations and tablet formulations. Injectable options include long-acting injection and short-acting injection, whereas tablet formulations focus on regular tablets. These delivery forms shape adherence protocols and administration settings across care pathways.

Patient population segmentation highlights adolescents receiving residential treatment or care under supervision, adults managed in inpatient or outpatient settings and the elderly benefiting from cognitive supervision or individualized care plans. Tailored approaches for each demographic underscore the importance of age-appropriate support and monitoring.

Distribution channels span hospital pharmacies in both private and public hospitals, online pharmacies operating via direct-to-consumer models and telemedicine platforms, retail pharmacies comprising independent stores and chain outlets, and specialty clinics such as addiction centers and rehabilitation facilities.

End-user analysis differentiates healthcare providers-addiction specialists, general physicians and psychiatrists-from patients who may be court-mandated or self-motivated. This dual perspective informs outreach strategies and program design.

Treatment initiatives are divided between government-led awareness campaigns and subsidized programs and private sector corporate wellness programs, each driving unique engagement and funding mechanisms.

Pharmacological properties are parsed by inhibitory effects, notably aldehyde dehydrogenase inhibition, and tolerability profile, addressing gastrointestinal effects and neuromuscular symptoms to optimize patient comfort and compliance.

Regional Dynamics Shaping Disulfiram Adoption and Access

In the Americas, established reimbursement frameworks and high prevalence of alcohol use disorders underpin robust adoption of Disulfiram. Private and public payers collaborate on subsidy programs, and telehealth integration accelerates access in remote areas. Europe, Middle East & Africa presents a mosaic of regulatory environments: Western Europe benefits from harmonized approval pathways, whereas MENA markets rely on government initiatives to expand addiction treatment infrastructure. Emerging markets within the region are prioritizing public awareness campaigns to reduce stigma and drive patient engagement.

Asia-Pacific is marked by rapid expansion of outpatient addiction services, increasing disposable incomes and enhanced digital health penetration. China and India are key epicenters, propelled by local manufacturing capacity and government-backed subsidy programs. Telemedicine platforms in Japan and Australia further extend patient monitoring and adherence support, while social destigmatization efforts in Southeast Asia create new engagement channels.

Competitive Landscape and Leading Company Strategies

The competitive landscape features global pharmaceutical giants and specialized generics manufacturers executing distinct strategies. Multinational innovators such as Abbott Laboratories, Allergan plc and Pfizer Inc. leverage robust R&D pipelines to explore novel delivery forms and combination therapies. Bayer AG and Merck KGaA emphasize incremental formulation enhancements and patent extensions to sustain differentiation.

Generics specialists including Aurobindo Pharma Limited, Cipla Inc. and Dr. Reddy’s Laboratories Ltd. compete on cost leadership, optimizing manufacturing scale and regional distribution to capture high-volume markets. Zydus Lifesciences Limited, Sun Pharmaceutical Industries Ltd. and Lupin Pharmaceuticals, Inc. focus on emerging markets and private sector partnerships to expand footprints.

Bausch Health Companies Inc., Aspen Pharmacare Holdings Limited and Torrent Pharmaceuticals Ltd. target niche segments, investing in long-acting injectable formulations and specialized patient support programs. Meanwhile, Novartis AG and Sanofi S.A. engage in strategic licensing and co-development agreements to broaden therapeutic scope. Collective M&A activity and alliance formation across the mid-sized and large-cap players underscore a race to secure value-added services, digital platforms and proprietary IP to bolster market share.

Actionable Recommendations for Industry Leaders

First, diversify API sourcing and invest in regional manufacturing hubs to reduce exposure to tariff fluctuations and ensure uninterrupted supply. Second, accelerate the development and commercialization of long-acting injectable Disulfiram formulations to improve patient adherence, differentiate product offerings and command premium pricing.

Third, cultivate partnerships with telemedicine platforms, specialty clinics and rehabilitation centers to integrate virtual monitoring, adherence tracking and behavioral support. Fourth, engage government stakeholders to shape subsidy programs and awareness campaigns that elevate public acceptance and reimbursement coverage. Fifth, deploy digital patient engagement tools-mobile apps, virtual coaching and real-time side-effect reporting-to enhance compliance and gather real-world evidence.

Finally, align portfolio strategies with region-specific dynamics by tailoring distribution models, pricing architectures and marketing initiatives to local regulatory environments and patient preferences, thereby unlocking incremental growth opportunities across mature and emerging markets.

Conclusion: Harnessing Opportunities in the Disulfiram Market

The Disulfiram market stands at a pivotal juncture, shaped by policy shifts, technological innovation and evolving patient care models. Transformative changes in therapy paradigms and digital engagement have redefined value creation, while 2025 tariffs underscore the need for resilient supply chains and dynamic pricing strategies. Multi-dimensional segmentation reveals nuanced patient and provider needs, and regional insights highlight diverse access pathways from the Americas to Asia-Pacific.

Leading companies are capitalizing on these dynamics through formulation advances, strategic alliances and market-specific tactics. Moving forward, stakeholders who invest in differentiation, embrace digital integration and foster public-private collaborations will secure competitive advantage. By aligning operational agility with deep market intelligence, decision-makers can navigate complexities, mitigate risks and unlock sustainable growth within the Disulfiram ecosystem.

Market Segmentation & Coverage

This research report categorizes the Disulfiram Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Alcohol Dependence
    • Long-Term Rehabilitation
    • Relapse Prevention
    • Short-Term Treatment
  • Antabuse Therapy
    • Combination Therapy
    • Monotherapy
  • Opioid Use Disorders
    • Adjunct Treatment
    • Maintenance Therapy
  • Injectable Formulation
    • Long-acting Injection
    • Short-acting Injection
  • Tablet Formulation
    • Regular Tab
  • Adolescents
    • Residential Treatment
    • Under Supervision
  • Adults
    • Inpatient
    • Outpatient
  • Elderly
    • Cognitive Supervision
    • Individualized Care
  • Hospital Pharmacies
    • Private Hospitals
    • Public Hospitals
  • Online Pharmacies
    • Direct-to-Consumer
    • Telemedicine Platforms
  • Retail Pharmacies
    • Independent Pharmacies
    • Pharmacy Chains
  • Specialty Clinics
    • Addiction Clinics
    • Rehabilitation Centers
  • Healthcare Providers
    • Addiction Specialists
    • General Physicians
    • Psychiatrists
  • Patients
    • Court-Mandated Patients
    • Self-Motivated Individuals
  • Government Initiatives
    • Awareness Campaigns
    • Subsidized Programs
  • Private Sector Initiatives
    • Corporate Wellness Programs
  • Inhibitory Effects
    • Aldehyde Dehydrogenase Inhibition
  • Tolerability Profile
    • Gastrointestinal Effects
    • Neuromuscular Symptoms

This research report categorizes the Disulfiram Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Disulfiram Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Alkem Laboratories Ltd.
  • Allergan plc
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Lupin Pharmaceuticals, Inc.
  • Merck KGaA
  • Mylan N.V.
  • Novartis AG
  • Odyssey pharmaceuticals inc
  • Par pharmaceutical inc
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Watson laboratories Inc.
  • Zydus Lifesciences Limited

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Disulfiram Market, by Therapeutic Application
8.1. Introduction
8.2. Alcohol Dependence
8.2.1. Long-Term Rehabilitation
8.2.2. Relapse Prevention
8.2.3. Short-Term Treatment
8.3. Antabuse Therapy
8.3.1. Combination Therapy
8.3.2. Monotherapy
8.4. Opioid Use Disorders
8.4.1. Adjunct Treatment
8.4.2. Maintenance Therapy
9. Disulfiram Market, by Formulation Type
9.1. Introduction
9.2. Injectable Formulation
9.2.1. Long-acting Injection
9.2.2. Short-acting Injection
9.3. Tablet Formulation
9.3.1. Regular Tab
10. Disulfiram Market, by Patient Population
10.1. Introduction
10.2. Adolescents
10.2.1. Residential Treatment
10.2.2. Under Supervision
10.3. Adults
10.3.1. Inpatient
10.3.2. Outpatient
10.4. Elderly
10.4.1. Cognitive Supervision
10.4.2. Individualized Care
11. Disulfiram Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.2.1. Private Hospitals
11.2.2. Public Hospitals
11.3. Online Pharmacies
11.3.1. Direct-to-Consumer
11.3.2. Telemedicine Platforms
11.4. Retail Pharmacies
11.4.1. Independent Pharmacies
11.4.2. Pharmacy Chains
11.5. Specialty Clinics
11.5.1. Addiction Clinics
11.5.2. Rehabilitation Centers
12. Disulfiram Market, by End-user Segments
12.1. Introduction
12.2. Healthcare Providers
12.2.1. Addiction Specialists
12.2.2. General Physicians
12.2.3. Psychiatrists
12.3. Patients
12.3.1. Court-Mandated Patients
12.3.2. Self-Motivated Individuals
13. Disulfiram Market, by Treatment Initiatives
13.1. Introduction
13.2. Government Initiatives
13.2.1. Awareness Campaigns
13.2.2. Subsidized Programs
13.3. Private Sector Initiatives
13.3.1. Corporate Wellness Programs
14. Disulfiram Market, by Pharmacological Properties
14.1. Introduction
14.2. Inhibitory Effects
14.2.1. Aldehyde Dehydrogenase Inhibition
14.3. Tolerability Profile
14.3.1. Gastrointestinal Effects
14.3.2. Neuromuscular Symptoms
15. Americas Disulfiram Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Disulfiram Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Disulfiram Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. Alkem Laboratories Ltd.
18.3.3. Allergan plc
18.3.4. Aspen Pharmacare Holdings Limited
18.3.5. Aurobindo Pharma Limited
18.3.6. Bausch Health Companies Inc.
18.3.7. Bayer AG
18.3.8. Cipla Inc.
18.3.9. Dr. Reddy's Laboratories Ltd.
18.3.10. Eli Lilly and Company
18.3.11. Lupin Pharmaceuticals, Inc.
18.3.12. Merck KGaA
18.3.13. Mylan N.V.
18.3.14. Novartis AG
18.3.15. Odyssey pharmaceuticals inc
18.3.16. Par pharmaceutical inc
18.3.17. Pfizer Inc.
18.3.18. Sanofi S.A.
18.3.19. Sun Pharmaceutical Industries Ltd.
18.3.20. Torrent Pharmaceuticals Ltd.
18.3.21. Watson laboratories Inc.
18.3.22. Zydus Lifesciences Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. DISULFIRAM MARKET MULTI-CURRENCY
FIGURE 2. DISULFIRAM MARKET MULTI-LANGUAGE
FIGURE 3. DISULFIRAM MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DISULFIRAM MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DISULFIRAM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DISULFIRAM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS DISULFIRAM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS DISULFIRAM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES DISULFIRAM MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES DISULFIRAM MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA DISULFIRAM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA DISULFIRAM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. DISULFIRAM MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. DISULFIRAM MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DISULFIRAM MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DISULFIRAM MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DISULFIRAM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DISULFIRAM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DISULFIRAM MARKET SIZE, BY ALCOHOL DEPENDENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DISULFIRAM MARKET SIZE, BY LONG-TERM REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DISULFIRAM MARKET SIZE, BY RELAPSE PREVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DISULFIRAM MARKET SIZE, BY SHORT-TERM TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DISULFIRAM MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DISULFIRAM MARKET SIZE, BY ANTABUSE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DISULFIRAM MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DISULFIRAM MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DISULFIRAM MARKET SIZE, BY ANTABUSE THERAPY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DISULFIRAM MARKET SIZE, BY OPIOID USE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DISULFIRAM MARKET SIZE, BY ADJUNCT TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DISULFIRAM MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DISULFIRAM MARKET SIZE, BY OPIOID USE DISORDERS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DISULFIRAM MARKET SIZE, BY INJECTABLE FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DISULFIRAM MARKET SIZE, BY LONG-ACTING INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DISULFIRAM MARKET SIZE, BY SHORT-ACTING INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DISULFIRAM MARKET SIZE, BY INJECTABLE FORMULATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DISULFIRAM MARKET SIZE, BY TABLET FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DISULFIRAM MARKET SIZE, BY REGULAR TAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DISULFIRAM MARKET SIZE, BY TABLET FORMULATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DISULFIRAM MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DISULFIRAM MARKET SIZE, BY RESIDENTIAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DISULFIRAM MARKET SIZE, BY UNDER SUPERVISION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DISULFIRAM MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DISULFIRAM MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DISULFIRAM MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DISULFIRAM MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DISULFIRAM MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DISULFIRAM MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DISULFIRAM MARKET SIZE, BY COGNITIVE SUPERVISION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DISULFIRAM MARKET SIZE, BY INDIVIDUALIZED CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DISULFIRAM MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DISULFIRAM MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DISULFIRAM MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DISULFIRAM MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DISULFIRAM MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DISULFIRAM MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DISULFIRAM MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DISULFIRAM MARKET SIZE, BY TELEMEDICINE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DISULFIRAM MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DISULFIRAM MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DISULFIRAM MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DISULFIRAM MARKET SIZE, BY PHARMACY CHAINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DISULFIRAM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DISULFIRAM MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DISULFIRAM MARKET SIZE, BY ADDICTION CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DISULFIRAM MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DISULFIRAM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DISULFIRAM MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DISULFIRAM MARKET SIZE, BY ADDICTION SPECIALISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DISULFIRAM MARKET SIZE, BY GENERAL PHYSICIANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DISULFIRAM MARKET SIZE, BY PSYCHIATRISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DISULFIRAM MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DISULFIRAM MARKET SIZE, BY PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DISULFIRAM MARKET SIZE, BY COURT-MANDATED PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL DISULFIRAM MARKET SIZE, BY SELF-MOTIVATED INDIVIDUALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL DISULFIRAM MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL DISULFIRAM MARKET SIZE, BY GOVERNMENT INITIATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL DISULFIRAM MARKET SIZE, BY AWARENESS CAMPAIGNS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL DISULFIRAM MARKET SIZE, BY SUBSIDIZED PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL DISULFIRAM MARKET SIZE, BY GOVERNMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL DISULFIRAM MARKET SIZE, BY PRIVATE SECTOR INITIATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL DISULFIRAM MARKET SIZE, BY CORPORATE WELLNESS PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL DISULFIRAM MARKET SIZE, BY PRIVATE SECTOR INITIATIVES, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL DISULFIRAM MARKET SIZE, BY INHIBITORY EFFECTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL DISULFIRAM MARKET SIZE, BY ALDEHYDE DEHYDROGENASE INHIBITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL DISULFIRAM MARKET SIZE, BY INHIBITORY EFFECTS, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL DISULFIRAM MARKET SIZE, BY TOLERABILITY PROFILE, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL DISULFIRAM MARKET SIZE, BY GASTROINTESTINAL EFFECTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL DISULFIRAM MARKET SIZE, BY NEUROMUSCULAR SYMPTOMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL DISULFIRAM MARKET SIZE, BY TOLERABILITY PROFILE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS DISULFIRAM MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS DISULFIRAM MARKET SIZE, BY ANTABUSE THERAPY, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS DISULFIRAM MARKET SIZE, BY OPIOID USE DISORDERS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS DISULFIRAM MARKET SIZE, BY INJECTABLE FORMULATION, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS DISULFIRAM MARKET SIZE, BY TABLET FORMULATION, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS DISULFIRAM MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS DISULFIRAM MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS DISULFIRAM MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS DISULFIRAM MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS DISULFIRAM MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS DISULFIRAM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS DISULFIRAM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS DISULFIRAM MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS DISULFIRAM MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS DISULFIRAM MARKET SIZE, BY GOVERNMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS DISULFIRAM MARKET SIZE, BY PRIVATE SECTOR INITIATIVES, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS DISULFIRAM MARKET SIZE, BY INHIBITORY EFFECTS, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS DISULFIRAM MARKET SIZE, BY TOLERABILITY PROFILE, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS DISULFIRAM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA DISULFIRAM MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA DISULFIRAM MARKET SIZE, BY ANTABUSE THERAPY, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA DISULFIRAM MARKET SIZE, BY OPIOID USE DISORDERS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA DISULFIRAM MARKET SIZE, BY INJECTABLE FORMULATION, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA DISULFIRAM MARKET SIZE, BY TABLET FORMULATION, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA DISULFIRAM MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA DISULFIRAM MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA DISULFIRAM MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA DISULFIRAM MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA DISULFIRAM MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA DISULFIRAM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA DISULFIRAM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA DISULFIRAM MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA DISULFIRAM MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA DISULFIRAM MARKET SIZE, BY GOVERNMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA DISULFIRAM MARKET SIZE, BY PRIVATE SECTOR INITIATIVES, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA DISULFIRAM MARKET SIZE, BY INHIBITORY EFFECTS, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA DISULFIRAM MARKET SIZE, BY TOLERABILITY PROFILE, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL DISULFIRAM MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL DISULFIRAM MARKET SIZE, BY ANTABUSE THERAPY, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL DISULFIRAM MARKET SIZE, BY OPIOID USE DISORDERS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL DISULFIRAM MARKET SIZE, BY INJECTABLE FORMULATION, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL DISULFIRAM MARKET SIZE, BY TABLET FORMULATION, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL DISULFIRAM MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL DISULFIRAM MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL DISULFIRAM MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL DISULFIRAM MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL DISULFIRAM MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL DISULFIRAM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL DISULFIRAM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL DISULFIRAM MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL DISULFIRAM MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL DISULFIRAM MARKET SIZE, BY GOVERNMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL DISULFIRAM MARKET SIZE, BY PRIVATE SECTOR INITIATIVES, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL DISULFIRAM MARKET SIZE, BY INHIBITORY EFFECTS, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL DISULFIRAM MARKET SIZE, BY TOLERABILITY PROFILE, 2018-2030 (USD MILLION)
TABLE 160. CANADA DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. CANADA DISULFIRAM MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 162. CANADA DISULFIRAM MARKET SIZE, BY ANTABUSE THERAPY, 2018-2030 (USD MILLION)
TABLE 163. CANADA DISULFIRAM MARKET SIZE, BY OPIOID USE DISORDERS, 2018-2030 (USD MILLION)
TABLE 164. CANADA DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 165. CANADA DISULFIRAM MARKET SIZE, BY INJECTABLE FORMULATION, 2018-2030 (USD MILLION)
TABLE 166. CANADA DISULFIRAM MARKET SIZE, BY TABLET FORMULATION, 2018-2030 (USD MILLION)
TABLE 167. CANADA DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 168. CANADA DISULFIRAM MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 169. CANADA DISULFIRAM MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 170. CANADA DISULFIRAM MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 171. CANADA DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. CANADA DISULFIRAM MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 173. CANADA DISULFIRAM MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 174. CANADA DISULFIRAM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 175. CANADA DISULFIRAM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 176. CANADA DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2018-2030 (USD MILLION)
TABLE 177. CANADA DISULFIRAM MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 178. CANADA DISULFIRAM MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 179. CANADA DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 180. CANADA DISULFIRAM MARKET SIZE, BY GOVERNMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 181. CANADA DISULFIRAM MARKET SIZE, BY PRIVATE SECTOR INITIATIVES, 2018-2030 (USD MILLION)
TABLE 182. CANADA DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2018-2030 (USD MILLION)
TABLE 183. CANADA DISULFIRAM MARKET SIZE, BY INHIBITORY EFFECTS, 2018-2030 (USD MILLION)
TABLE 184. CANADA DISULFIRAM MARKET SIZE, BY TOLERABILITY PROFILE, 2018-2030 (USD MILLION)
TABLE 185. MEXICO DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. MEXICO DISULFIRAM MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 187. MEXICO DISULFIRAM MARKET SIZE, BY ANTABUSE THERAPY, 2018-2030 (USD MILLION)
TABLE 188. MEXICO DISULFIRAM MARKET SIZE, BY OPIOID USE DISORDERS, 2018-2030 (USD MILLION)
TABLE 189. MEXICO DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 190. MEXICO DISULFIRAM MARKET SIZE, BY INJECTABLE FORMULATION, 2018-2030 (USD MILLION)
TABLE 191. MEXICO DISULFIRAM MARKET SIZE, BY TABLET FORMULATION, 2018-2030 (USD MILLION)
TABLE 192. MEXICO DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 193. MEXICO DISULFIRAM MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 194. MEXICO DISULFIRAM MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 195. MEXICO DISULFIRAM MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 196. MEXICO DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. MEXICO DISULFIRAM MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 198. MEXICO DISULFIRAM MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 199. MEXICO DISULFIRAM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 200. MEXICO DISULFIRAM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 201. MEXICO DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2018-2030 (USD MILLION)
TABLE 202. MEXICO DISULFIRAM MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 203. MEXICO DISULFIRAM MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 204. MEXICO DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 205. MEXICO DISULFIRAM MARKET SIZE, BY GOVERNMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 206. MEXICO DISULFIRAM MARKET SIZE, BY PRIVATE SECTOR INITIATIVES, 2018-2030 (USD MILLION)
TABLE 207. MEXICO DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2018-2030 (USD MILLION)
TABLE 208. MEXICO DISULFIRAM MARKET SIZE, BY INHIBITORY EFFECTS, 2018-2030 (USD MILLION)
TABLE 209. MEXICO DISULFIRAM MARKET SIZE, BY TOLERABILITY PROFILE, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES DISULFIRAM MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES DISULFIRAM MARKET SIZE, BY ANTABUSE THERAPY, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES DISULFIRAM MARKET SIZE, BY OPIOID USE DISORDERS, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES DISULFIRAM MARKET SIZE, BY INJECTABLE FORMULATION, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES DISULFIRAM MARKET SIZE, BY TABLET FORMULATION, 2018-2030 (USD MILLION)
TABLE 217. UNITED STATES DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 218. UNITED STATES DISULFIRAM MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES DISULFIRAM MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES DISULFIRAM MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES DISULFIRAM MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES DISULFIRAM MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES DISULFIRAM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES DISULFIRAM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2018-2030 (USD MILLION)
TABLE 227. UNITED STATES DISULFIRAM MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 228. UNITED STATES DISULFIRAM MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 229. UNITED STATES DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 230. UNITED STATES DISULFIRAM MARKET SIZE, BY GOVERNMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 231. UNITED STATES DISULFIRAM MARKET SIZE, BY PRIVATE SECTOR INITIATIVES, 2018-2030 (USD MILLION)
TABLE 232. UNITED STATES DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2018-2030 (USD MILLION)
TABLE 233. UNITED STATES DISULFIRAM MARKET SIZE, BY INHIBITORY EFFECTS, 2018-2030 (USD MILLION)
TABLE 234. UNITED STATES DISULFIRAM MARKET SIZE, BY TOLERABILITY PROFILE, 2018-2030 (USD MILLION)
TABLE 235. UNITED STATES DISULFIRAM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY ANTABUSE THERAPY, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY OPIOID USE DISORDERS, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY INJECTABLE FORMULATION, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY TABLET FORMULATION, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 252. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2018-2030 (USD MILLION)
TABLE 253. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 254. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 255. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 256. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY GOVERNMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 257. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY PRIVATE SECTOR INITIATIVES, 2018-2030 (USD MILLION)
TABLE 258. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2018-2030 (USD MILLION)
TABLE 259. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY INHIBITORY EFFECTS, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY TOLERABILITY PROFILE, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC DISULFIRAM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA DISULFIRAM MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA DISULFIRAM MARKET SIZE, BY ANTABUSE THERAPY, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA DISULFIRAM MARKET SIZE, BY OPIOID USE DISORDERS, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA DISULFIRAM MARKET SIZE, BY INJECTABLE FORMULATION, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA DISULFIRAM MARKET SIZE, BY TABLET FORMULATION, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA DISULFIRAM MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA DISULFIRAM MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA DISULFIRAM MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA DISULFIRAM MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 275. AUSTRALIA DISULFIRAM MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 276. AUSTRALIA DISULFIRAM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 277. AUSTRALIA DISULFIRAM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 278. AUSTRALIA DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2018-2030 (USD MILLION)
TABLE 279. AUSTRALIA DISULFIRAM MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 280. AUSTRALIA DISULFIRAM MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 281. AUSTRALIA DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 282. AUSTRALIA DISULFIRAM MARKET SIZE, BY GOVERNMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 283. AUSTRALIA DISULFIRAM MARKET SIZE, BY PRIVATE SECTOR INITIATIVES, 2018-2030 (USD MILLION)
TABLE 284. AUSTRALIA DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2018-2030 (USD MILLION)
TABLE 285. AUSTRALIA DISULFIRAM MARKET SIZE, BY INHIBITORY EFFECTS, 2018-2030 (USD MILLION)
TABLE 286. AUSTRALIA DISULFIRAM MARKET SIZE, BY TOLERABILITY PROFILE, 2018-2030 (USD MILLION)
TABLE 287. CHINA DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. CHINA DISULFIRAM MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 289. CHINA DISULFIRAM MARKET SIZE, BY ANTABUSE THERAPY, 2018-2030 (USD MILLION)
TABLE 290. CHINA DISULFIRAM MARKET SIZE, BY OPIOID USE DISORDERS, 2018-2030 (USD MILLION)
TABLE 291. CHINA DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 292. CHINA DISULFIRAM MARKET SIZE, BY INJECTABLE FORMULATION, 2018-2030 (USD MILLION)
TABLE 293. CHINA DISULFIRAM MARKET SIZE, BY TABLET FORMULATION, 2018-2030 (USD MILLION)
TABLE 294. CHINA DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 295. CHINA DISULFIRAM MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 296. CHINA DISULFIRAM MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 297. CHINA DISULFIRAM MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 298. CHINA DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. CHINA DISULFIRAM MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 300. CHINA DISULFIRAM MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 301. CHINA DISULFIRAM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 302. CHINA DISULFIRAM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 303. CHINA DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2018-2030 (USD MILLION)
TABLE 304. CHINA DISULFIRAM MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 305. CHINA DISULFIRAM MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 306. CHINA DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 307. CHINA DISULFIRAM MARKET SIZE, BY GOVERNMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 308. CHINA DISULFIRAM MARKET SIZE, BY PRIVATE SECTOR INITIATIVES, 2018-2030 (USD MILLION)
TABLE 309. CHINA DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2018-2030 (USD MILLION)
TABLE 310. CHINA DISULFIRAM MARKET SIZE, BY INHIBITORY EFFECTS, 2018-2030 (USD MILLION)
TABLE 311. CHINA DISULFIRAM MARKET SIZE, BY TOLERABILITY PROFILE, 2018-2030 (USD MILLION)
TABLE 312. INDIA DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 313. INDIA DISULFIRAM MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 314. INDIA DISULFIRAM MARKET SIZE, BY ANTABUSE THERAPY, 2018-2030 (USD MILLION)
TABLE 315. INDIA DISULFIRAM MARKET SIZE, BY OPIOID USE DISORDERS, 2018-2030 (USD MILLION)
TABLE 316. INDIA DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 317. INDIA DISULFIRAM MARKET SIZE, BY INJECTABLE FORMULATION, 2018-2030 (USD MILLION)
TABLE 318. INDIA DISULFIRAM MARKET SIZE, BY TABLET FORMULATION, 2018-2030 (USD MILLION)
TABLE 319. INDIA DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 320. INDIA DISULFIRAM MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 321. INDIA DISULFIRAM MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 322. INDIA DISULFIRAM MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 323. INDIA DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 324. INDIA DISULFIRAM MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 325. INDIA DISULFIRAM MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 326. INDIA DISULFIRAM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 327. INDIA DISULFIRAM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 328. INDIA DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2018-2030 (USD MILLION)
TABLE 329. INDIA DISULFIRAM MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 330. INDIA DISULFIRAM MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 331. INDIA DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 332. INDIA DISULFIRAM MARKET SIZE, BY GOVERNMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 333. INDIA DISULFIRAM MARKET SIZE, BY PRIVATE SECTOR INITIATIVES, 2018-2030 (USD MILLION)
TABLE 334. INDIA DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2018-2030 (USD MILLION)
TABLE 335. INDIA DISULFIRAM MARKET SIZE, BY INHIBITORY EFFECTS, 2018-2030 (USD MILLION)
TABLE 336. INDIA DISULFIRAM MARKET SIZE, BY TOLERABILITY PROFILE, 2018-2030 (USD MILLION)
TABLE 337. INDONESIA DISULFIRAM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 338. INDONESIA DISULFIRAM MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 339. INDONESIA DISULFIRAM MARKET SIZE, BY ANTABUSE THERAPY, 2018-2030 (USD MILLION)
TABLE 340. INDONESIA DISULFIRAM MARKET SIZE, BY OPIOID USE DISORDERS, 2018-2030 (USD MILLION)
TABLE 341. INDONESIA DISULFIRAM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 342. INDONESIA DISULFIRAM MARKET SIZE, BY INJECTABLE FORMULATION, 2018-2030 (USD MILLION)
TABLE 343. INDONESIA DISULFIRAM MARKET SIZE, BY TABLET FORMULATION, 2018-2030 (USD MILLION)
TABLE 344. INDONESIA DISULFIRAM MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 345. INDONESIA DISULFIRAM MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 346. INDONESIA DISULFIRAM MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 347. INDONESIA DISULFIRAM MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 348. INDONESIA DISULFIRAM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 349. INDONESIA DISULFIRAM MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 350. INDONESIA DISULFIRAM MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 351. INDONESIA DISULFIRAM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 352. INDONESIA DISULFIRAM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 353. INDONESIA DISULFIRAM MARKET SIZE, BY END-USER SEGMENTS, 2018-2030 (USD MILLION)
TABLE 354. INDONESIA DISULFIRAM MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 355. INDONESIA DISULFIRAM MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 356. INDONESIA DISULFIRAM MARKET SIZE, BY TREATMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 357. INDONESIA DISULFIRAM MARKET SIZE, BY GOVERNMENT INITIATIVES, 2018-2030 (USD MILLION)
TABLE 358. INDONESIA DISULFIRAM MARKET SIZE, BY PRIVATE SECTOR INITIATIVES, 2018-2030 (USD MILLION)
TABLE 359. INDONESIA DISULFIRAM MARKET SIZE, BY PHARMACOLOGICAL PROPERTIES, 2018-2030 (USD MIL

Companies Mentioned

  • Abbott Laboratories
  • Alkem Laboratories Ltd.
  • Allergan plc
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Lupin Pharmaceuticals, Inc.
  • Merck KGaA
  • Mylan N.V.
  • Novartis AG
  • Odyssey pharmaceuticals inc
  • Par pharmaceutical inc
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Watson laboratories Inc.
  • Zydus Lifesciences Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Disulfiram Market by Indication, Distribution Channel - Global Forecast 2025-2030 - Product Image

Disulfiram Market by Indication, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Disulfiram (CAS 97-77-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Disulfiram (CAS 97-77-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Addictions Therapeutics Market Report 2025 - Product Image

Addictions Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Substance Abuse Treatment Market by Substance Abuse Type, Product, Treatment Option, Distribution Channel - Global Forecast 2025-2030 - Product Image

Substance Abuse Treatment Market by Substance Abuse Type, Product, Treatment Option, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Cocaine Use Disorder - Pipeline Insight, 2025 - Product Image

Cocaine Use Disorder - Pipeline Insight, 2025

  • Clinical Trials
  • 50 Pages
  • Global
From

About the Market

The Disulfiram market is a segment of the Addiction Disorders Drugs market. Disulfiram is a medication used to treat alcohol use disorder (AUD). It works by blocking the breakdown of alcohol, causing unpleasant side effects when alcohol is consumed. It is used as an aid to help people abstain from drinking alcohol. Disulfiram is available in tablet form and is taken orally. It is also available in an injectable form. The Disulfiram market is highly competitive, with many companies offering generic versions of the drug. Companies in the market include Mylan, Teva Pharmaceuticals, Sun Pharmaceuticals, Dr. Reddy's Laboratories, and Cipla. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.